News
-
-
PRESS RELEASE
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven. Shield Therapeutics increasing physician awareness for ACCRUFeR® sales traction -
-
-
-
PRESS RELEASE
Hardman & Co Investor Forum Research on Windward (WNWD): High-growth maritime artificial intelligence play
Hardman & Co Investor Forum Research on Windward (WNWD): Explore the high-growth maritime artificial intelligence opportunities provided by Windward's AI-powered decision platform in the global maritime industry -
-
PRESS RELEASE
Hardman & Co Research on Duke Capital (DUKE): Taking Duke Capital to the next level
Hardman & Co Research provides an update on Duke Capital (DUKE) and its strategies to enhance returns through equity and debt optimization. Details include equity issue for growth and progress on a third-party capital model -
-
PRESS RELEASE
Hardman & Co Q&A on ICG Enterprise Trust (ICGT): Operating companies’ widening margins and strong EBITDA growth
Hardman & Co Research provides Q&A session on ICG Enterprise Trust focusing on widening margins and strong EBITDA growth. Analyst Mark Thomas discusses key topics and Trust's performance
